Evidence map›Paper›PMID 39867926›Full record

ArticleFrontiers in medicine2024

Comparison of good review practices of seven countries participating in the ECOWAS medicines regulatory harmonisation initiative: identifying opportunities for improvement.

Mercy Owusu-Asante, Delese Mimi Darko, Seth Seaneke, Aminata Nacoulma, Oula Ibrahim Olivier Traore, Christianah Mojisola Adeyeye, Abayomi Akinyemi, Coulibaly Assane, Clarisse Épse Kaul Meledje Clamoungou, Oumy Kalsoum Ndao and 7 more

Abstract read
In one paragraph

Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Mercy Owusu-AsanteSchool of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.
Delese Mimi DarkoFood and Drugs Authority, Accra, Ghana.
Seth SeanekeFood and Drugs Authority, Accra, Ghana.
Aminata NacoulmaNational Pharmaceutical Regulatory Agency, Ouagadougou, Burkina Faso.
Oula Ibrahim Olivier TraoreNational Pharmaceutical Regulatory Agency, Ouagadougou, Burkina Faso.
Christianah Mojisola AdeyeyeNational Agency for Food and Drug Administration and Control, Abuja, Nigeria.
Abayomi AkinyemiNational Agency for Food and Drug Administration and Control, Abuja, Nigeria.
Coulibaly AssaneMinistry of Public Health, Abidjan, Côte d'Ivoire.
Clarisse Épse Kaul Meledje ClamoungouMinistry of Public Health, Abidjan, Côte d'Ivoire.
Oumy Kalsoum NdaoMinistry of Health and Social Welfare, Dakar, Senegal.
Rokhaya Ndiaye KandeMinistry of Health and Social Welfare, Dakar, Senegal.
James KomehPharmacy Board of Sierra Leone, Freetown, Sierra Leone.
Sheku MansarayPharmacy Board of Sierra Leone, Freetown, Sierra Leone.
Dalkoi LamboniMedicine and Laboratories, Lome, Togo.
Maheza AgbaMedicine and Laboratories, Lome, Togo.
Stuart WalkerSchool of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.
Sam SalekSchool of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: When implemented by national and regional regulatory agencies good review practices (GRevPs) support the timely high-quality review of medicines for enhanced patients' availability to safe, quality and efficacious innovative and generic products. It is important that all aspects of GRevPs are continuously evaluated and updated to promote the continuous improvement of regulatory systems at national and regional levels. The aim of this study was to assess and compare the GRevPs of the national medicines regulatory agencies (NMRAs) of Burkina Faso, Cote d'Ivoire, Ghana, Nigeria, Senegal, Sierra Leone and Togo, who are active participants of the ECOWASMRH initiative to identify opportunities for improvement. Methods: The Optimising Efficiencies in Regulatory Agencies questionnaire, was completed by each of the NMRAs, which facilitates the assessment of GRevPs, which in turn affect the regulatory review processes. Results: Except for Cote d'Ivoire and Nigeria which are autonomous, the other five NMRAs operate within the administrative structure of their respective Health Ministry, to regulate medical products for human use, medical devices and diagnostics. Apart from Togo, the agencies receive partial funding from their governments as well as from regulatory fees. Population in the seven countries ranges from 8.6 million to 211.4 million. All the NMRAs had measures in place to achieve quality in their review processes, although there were some remaining initiatives related to transparency and communication, continuous improvement and training and education, to be implemented. Of the ten quality decision-making practices Ghana had implemented nine into a framework, Togo eight, Cote d'Ivoire seven, Nigeria six, and Burkina Faso five; while Sierra Leone has partially implemented all ten and Senegal had not implemented any of the quality decision-making practices. Conclusion: The study compared the organisation, GRevPs and quality decision-making processes of the NMRAs that actively participate in the ECOWAS-MRH initiative. Though some differences were identified with regard to organisation, a significant number of good review practice initiatives and quality decision-making practices were identified yet to be implemented to promote continuous improvement in the regulatory processes of the NMRAs.

Indexed as

African Medicines Agency (AMA)Economic Community of West African States Medicines Regulatory Harmonisation (ECOWAS-MRH)good review practicesOptimising Efficiencies in Regulatory Agencies (OpERA)regulatory reliance

Identifiers

PMID39867926
PMCPMC11757867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.